Search | OpenScholar

Search results

193 results found

Standing and Supine Blood Pressure Outcomes Associated With Droxidopa and Midodrine in Patients With Neurogenic Orthostatic Hypotension: A Bayesian Meta-analysis and Mixed Treatment Comparison of Randomized Trials. 2018;52:1182-1194.

Publication: Journal Article

Chen, JJ, Y Han, J Tang, L Portillo, RA Hauser, and K Dashtipour. 2018. “Standing and Supine Blood Pressure Outcomes Associated With Droxidopa and Midodrine in Patients With Neurogenic Orthostatic Hypotension: A Bayesian Meta-Analysis and Mixed Treatment Comparison of Randomized Trials. 2018;52:1182-1194.”. Ann Pharmacother.

A mixed treatment comparison to compare the efficacy and safety of botulinum toxin treatments for cervical dystonia. J Neurol 2016;263:772-780.

Publication: Journal Article

Han, Y, AL Stevens, K Dashtipour, RA Hauser, and Z Mari. 2016. “A Mixed Treatment Comparison to Compare the Efficacy and Safety of Botulinum Toxin Treatments for Cervical Dystonia. J Neurol 2016;263:772-780.”. J Neurol.

Expanding phenomenologic heterogeneity of tardive syndromes: Time for an updated assessment tool. Parkinsonism Relat Disord 2020;77:141-145.

Publication: Journal Article

Bhidayasiri, R, JM Kane, KP Frei, SN Caroff, CU Correll, S Fahn, J Jankovic, RA Hauser, and DD Truong. 2020. “Expanding Phenomenologic Heterogeneity of Tardive Syndromes: Time for an Updated Assessment Tool. Parkinsonism Relat Disord 2020;77:141-145.”. Parkonsonism Relat Disord.

Communicating with participants during the conduct of multi-center clinical trials. Clin Trials 2016;13:592-596.

Publication: Journal Article

Augustine, EF, ER Dorsey, RA Hauser, JJ Elm, BC Tilley, and KK Kieburtz. 2016. “Communicating With Participants During the Conduct of Multi-Center Clinical Trials. Clin Trials 2016;13:592-596.”. Clin Trials.

Levodopa-carbidopa intestinal gelin advanced Parkinson's disease: Final 12-month, open-label results. Mov Disord 2015;30:500-9.

Publication: Journal Article

Fernandez, HH, DG Standaert, RA Hauser, AE Lang, VS Fung, F Klostermann, MF Lew, et al. 2015. “Levodopa-Carbidopa Intestinal Gelin Advanced Parkinson’s Disease: Final 12-Month, Open-Label Results. Mov Disord 2015;30:500-9.”. Mov Disord.

α-Synuclein in Parkinson's disease: getting to the core of the matter. Lancet Neurol 2015;14:785-6.

Publication: Journal Article

Hauser, RA. 2015. “α-Synuclein in Parkinson’s Disease: Getting to the Core of the Matter. Lancet Neurol 2015;14:785-6.”. Lancet Neurol.

Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD). Mov Disord 2013;28:1823-31.

Publication: Journal Article

Group, Parkinson Study. 2013. “Phase II Safety, Tolerability, and Dose Selection Study of Isradipine As a Potential Disease-Modifying Intervention in Early Parkinson’s Disease (STEADY-PD). Mov Disord 2013;28:1823-31.”. Mov Disord.

IPX066: a novel carbidopa-levodopa extended-release formulation. Expert Rev Neurother. 2012;12:133-40.

Publication: Journal Article

Hauser, RA. 2012. “IPX066: a Novel Carbidopa-Levodopa Extended-Release Formulation. Expert Rev Neurother. 2012;12:133-40.”. Expert Rev Neurother.

Design innovations and baseline findings in a long-term Parkinson’s trial: The national institute of neurological disorders and stroke exploratory trials in Parkinson’s Disease Long-Term Study-1. Mov Disord 2012; 27:1513-1521.

Publication: Journal Article

Elm, JJ, and The NINDS NET-PD Investigators. 2012. “Design Innovations and Baseline Findings in a Long-Term Parkinson’s Trial: The National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson’s Disease Long-Term Study-1. Mov Disord 2012; 27:1513-1521.”. Mov Disord.

MicroRNAs regulation in Parkinson’s disease, and their potential role as diagnostic and therapeutic targets

Publication: Journal Article

Shaheen, Nour, Ahmed Shaheen, Mahmoud Osama, Abdulqadir J. Nashwan, Vishal Bharmauria, and Oliver Flouty. 2024. “MicroRNAs Regulation in Parkinson’s Disease, and Their Potential Role As Diagnostic and Therapeutic Targets”. Npj Parkinson’s Disease.